Tumor News and Research

RSS

Patients who receive H-SRT for recurrent brain cancer live longer: Researchers

Patients who received hypofractionated stereotactic radiotherapy for their recurrent brain cancers lived longer lives, according to researchers at Thomas Jefferson University.

18 May 2010

152 research and training grants awarded to researchers at 93 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 152 new national research and training grants totaling $50,717,000 in the first of two grants cycles for 2010. The grants, primarily to early career researchers, cover a broad range of investigator-initiated ideas at 93 institutions nationwide, from whether cadmium exposure increases the risk of endometrial cancer, to studies of plant and bacterial-bourne compounds, to a study on a protein called survivin that could lead to novel drugs targeting prostate cancer.

18 May 2010

No clear evidence of a mobile phone and brain cancer link

Use of mobile phones has been under scrutiny for a while now with many claiming a link between mobile phone use and brain cancer. The mild radioactive waves generated from mobile phones have so far been poorly understood. There are no known mechanisms by which mobile phone radiation could cause cancer. Unlike x-rays, mobile phone radiation is non-ionising, and is too weak to break apart DNA, which is necessary to induce other cancers. However scientists do agree that this radiation might speed up a growing brain tumor.

17 May 2010

Hawthorn announces licensing deal with University of Pittsburgh for novel monoclonal antibodies for cancer

Hawthorn Pharmaceuticals, Inc. today announced a global licensing deal with the University of Pittsburgh covering a series of novel monoclonal antibodies for cancer. The antibody portfolio targets a variety of cancers through the cell surface chondrotin sulfate proteoglycan 4 (CSPG4), which plays an important role in signaling pathways regulating tumor cell survival, growth, and motility.

17 May 2010

Celldex Therapeutics commences screening in CDX-1307 Phase 2 study for bladder cancer

Celldex Therapeutics, Inc. today announced that the first patient has been screened in a randomized Phase 2 study of the Company's novel, first-in-class antibody-based vaccine candidate from its Precision Targeted Immunotherapy (PTI) platform. This study will evaluate the CDX-1307 regimen in both neoadjuvant and adjuvant settings in patients with newly diagnosed muscle-invasive bladder cancers that express hCG-beta.

17 May 2010

Most recurrences of HCC occur early after initial diagnosis and treatment: Research article

Hepatocellular carcinoma is an aggressive tumor with poor long-term prognosis. The reported 5-year recurrence rate ranges from 75% to 100%. Therefore, extrahepatic metastasis of HCC is uncommon due to the highly malignant nature of the primary tumor. However, with advances in different treatment modalities for HCC, the incidence of extrahepatic metastasis appears to be increasing.

17 May 2010

Researchers identify protein involved in pushing bladder tumors to become invasive

Bladder cancer often becomes aggressive and spreads in patients despite treatment, but now researchers at the Kimmel Cancer Center at Jefferson have identified a protein they believe is involved in pushing tumors to become invasive - and deadly.

15 May 2010

Canadian cancer patients cross the border for second opinion

Two years ago, Beverlee London of Toronto was diagnosed with Stage I lung cancer. London was given the news by her lung specialist in Toronto that she had a malignant tumor on her right lung. She also decided at the time to visit the Barbara Ann Karmanos Cancer Center in Detroit for a second opinion, since she had family living in the area.

15 May 2010

U.S. Patent and Trademark Office grants patent to Historx's AQUA technology

HistoRx , Inc., announced today that the U.S. Patent and Trademark Office has granted a patent protecting the company's methods for determining a cancer patient's prognosis based on sub-cellular localization of biomarkers.

15 May 2010

Still River Systems announces clinical beam extraction from world's smallest high-energy proton therapy accelerator

Still River Systems, Inc. announces successful clinical beam extraction from the first production unit of the world's smallest high-energy proton therapy accelerator. Powerful proton beams are used for the precise treatment of cancer by delivering a highly focused beam of radiation to the tumor while reducing the damage to surrounding healthy tissue and vital organs.

15 May 2010

Amgen submits BLA for denosumab subcutaneous RANK Ligand inhibitor

Amgen Inc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denosumab, a subcutaneous RANK Ligand inhibitor. The BLA submission summarizes clinical experience from nearly 6,900 patients across 18 clinical studies, including approximately 5,700 patients with advanced cancer in the three, pivotal, Phase 3, head-to-head trials versus Zometa® (zoledronic acid).

15 May 2010

Measuring gene expression in healthy women may predict future breast cancer risk, say scientists

Researchers at Georgetown Lombard Comprehensive Cancer Center have been able to show, in mice, how just a little adjustment in the expression of two common genes can promote the kind of cellular changes that led to breast cancer. They say these tweaks likely mimic natural variation women have in expression of the two genes.

14 May 2010

RMEI, PIM sponsor continuing education series on castration-resistant prostate cancer

Castration-resistant prostate cancer (CRPC), defined as tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Current treatment regimens are complicated by toxicities and a low rate of relapse-free survival. Many novel therapies in clinical trials offer hope for patients with this challenging diagnosis. Healthcare professionals who are treating CRPC must stay abreast of these emerging therapies to ensure optimal care for these patients.

14 May 2010

Experts address fundamental questions related to renal failure in ICU

Despite the fact that recent medical advances have allowed healthcare professionals to stabilize patients who would have otherwise died, many stabilized patients later develop organ system failure. In fact, acute renal failure is one of the biggest threats to critically ill patients: forty percent of patients with this condition die.

14 May 2010

Each melanoma cell capable of cancer stem cell behavior: Study

Scientists at The Wistar Institute offer a new explanation for the persistent ability of melanoma cells to self-renew, one of the reasons why melanoma remains the deadliest form of skin cancer. The concept of the "dynamic stemness" of melanoma can explain why melanoma cells behave like both conventional tumor cells and cancer stem cells.

14 May 2010

Response Genetics first-quarter total revenue up 140%

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three months ended March 31, 2010.

14 May 2010

TechniScan awarded U.S. Patent for 3-D, Warm Bath Ultrasound system

A newly awarded U.S. Patent will protect TechniScan, Inc's., novel way to image, biopsy and treat breast cancer.

13 May 2010

Research article focuses on how IECs respond to probiotic strain B. lactis HN019

Probiotics are a group of live microorganisms administered in adequate amounts which confer a beneficial health effect on the host. This bacterial community plays a pivotal role in human nutrition and health by promoting the supply of nutrients, preventing pathogen colonization and shaping and maintaining normal mucosal immunity.

13 May 2010

Research investigates MDR in human HCC

Hepatocellular carcinoma responds poorly to chemotherapy owing to MDR. Recent studies have shown the tumors derived from the colon, kidney, or adrenal cortex, and HCC exhibited overexpression of MDR1/P-gp. This overexpression results in a primary MDR phenotype of these cancers.

13 May 2010

Researchers develop new approach to immunotherapy of cancer

Harnessing the immune system is emerging as one of the most promising new ways to fight cancer. Most cancer cells are eliminated by the immune system; however, over a lifetime, a few may escape this immune surveillance and lead to tumors and metastases. Hence a formidable opportunity has been to find ways to make the immune system recognize the tumor as a foreign body and trigger a response.

13 May 2010

Tumor News and Research

Patients who receive H-SRT for recurrent brain cancer live longer: Researchers

152 research and training grants awarded to researchers at 93 institutions nationwide

No clear evidence of a mobile phone and brain cancer link

Hawthorn announces licensing deal with University of Pittsburgh for novel monoclonal antibodies for cancer

Celldex Therapeutics commences screening in CDX-1307 Phase 2 study for bladder cancer

Most recurrences of HCC occur early after initial diagnosis and treatment: Research article

Researchers identify protein involved in pushing bladder tumors to become invasive

Canadian cancer patients cross the border for second opinion

U.S. Patent and Trademark Office grants patent to Historx's AQUA technology

Still River Systems announces clinical beam extraction from world's smallest high-energy proton therapy accelerator

Amgen submits BLA for denosumab subcutaneous RANK Ligand inhibitor

Measuring gene expression in healthy women may predict future breast cancer risk, say scientists

RMEI, PIM sponsor continuing education series on castration-resistant prostate cancer

Experts address fundamental questions related to renal failure in ICU

Each melanoma cell capable of cancer stem cell behavior: Study

Response Genetics first-quarter total revenue up 140%

TechniScan awarded U.S. Patent for 3-D, Warm Bath Ultrasound system

Research article focuses on how IECs respond to probiotic strain B. lactis HN019

Research investigates MDR in human HCC

Researchers develop new approach to immunotherapy of cancer

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News